Dengue vaccine unit dose and administration thereof
AssigneeTakeda Vaccines, Inc.
InventorDerek WALLACE
Life of this patent
Estimating the term…
Abstract
The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.
Claims36
(canceled)
A method for vaccinating against dengue disease in a subject or a subject population, the method comprising administering to the subject or subject population a dengue virus composition that results in a vaccine efficacy of at least 60% against dengue serotype 2 which is represented by at least 60% reduction in dengue disease occurrence attributed to dengue serotype 2 in vaccinated subjects compared to unvaccinated subjects.
A method for vaccinating against dengue disease in a subject or a subject population in each of seropositive subjects and seronegative subjects, the method comprising administering to the subject or subject population, a dengue virus composition that results in a vaccine efficacy of at least 60% against dengue serotype 2, wherein the dengue virus composition comprises a non-chimeric dengue serotype 2 comprising a nucleotide sequence operable to encode an amino acid sequence of SEQ ID NO:
- 4.
Dependencies are inferred from the claim text.